Biotecnologicas

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8868
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 11 Jul 2013 19:12

Determined to emerge as a leading force in the global drug development business, China has invested a total of more than $160 billion in building its biotech industry, according to a new assessment from Lux Research. And with 15 clusters--including 5 fast-growing "super" clusters--the huge Asian market is poised to leap past Japan and take the number two spot in terms of overall R&D spending on drug development.

Taking a distinctly bullish tone, Lux reports that the fast-growing biotech sector is evolving from basic research toward late-stage efforts and commercialization as more drugs are approved for use in China. Over the past four years China's native R&D industry--distinct from the Big Pharma operations that have been growing there--has produced more than 3,000 patents and 12 new drugs. And the country's economic czars plan to see that number of innovative new drugs swell to 100 by 2020.

That approval pace would average about 12 new drugs a year for the next 8 years, compared to 39 new chemical entities OK'd by the FDA last year.

Most of these new drugs should be for cancer. Fifty-six of China's 127 "Major New Drug Innovation Program" projects seek to develop drugs to treat cancer. Biologics outnumber small molecule drugs by a large margin--34 for biologics versus only 22 for small molecule drugs. And it's only a matter of time before China's biotech industry looks abroad.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8868
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 15 Jul 2013 13:41

Over the last two decades the treatment of HIV and Aids has been transformed.

Once viewed as a "death sentence", new therapies have improved survival rates for those with access to the latest drugs so much, that it is now considered a chronic illness.

While death rates remain high in Africa, and other poor countries, the number of people dying in developed countries is now very low.

Sadly, far less progress has been made in treating hepatitis C. This "silent killer" now kills more people in the US than Aids does.

However, one biotech company is on the verge of a new approach that could make the disease far more treatable.

Hepatitis C is a disease transmitted through contact with infected blood. It can lie dormant for years. But ultimately it can lead to either liver failure or cancer – both of which have a high mortality rate.

The latest estimate suggests that as many as 3% of American "baby boomers" (those born between 1945 and 65) could have the disease. Overall, 3.2m are infected in the US alone, and up to 200m people worldwide.

And of them all, Sam Isaly of the Worldwide Healthcare Trust believes the most promising is one discovered by biotech firm Gilead (Nasdaq: GILD).

A frequent problem with complicated treatment regimes – such as the one for hepatitis C - is that patients end up being unable to follow the regime to the letter.

So one big benefit of Gilead's treatment is that it simplifies the process. It removes the need for regular injections of interferon and other medications, and replaces them with a one-a-day pill.

Trials suggest that this dramatically boosts the treatment success rate – by up to 100% – while cutting down the number of side effects. The treatment period is also far shorter.

If you'd rather invest in the sector via a fund, then both the London-listed Biotech Growth Trust (LSE: BIOG) and the Worldwide Healthcare Trust (LSE: WWH) own Gilead as part of their top 10 holdings.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8868
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 22 Jul 2013 10:41

A new ‘intelligent knife’ has been developed for surgery which can identify the presence of cancerous cells. The knife can provide instant information to the surgeon, making operations much quicker and safer.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8868
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 16 Sep 2013 05:41

Reprogramar células adultas para que retornen al estado de células embrionarias pluripotentes en un ratón vivo en lugar de en un caldo de cultivo parece algo muy difícil. ¿Qué avances han permitido este logro tan impactante? Hay unos 200 tipos diferentes de células en el cuerpo humano. Una neurona, una célula de la piel o un glóbulo rojo de la sangre parecen células muy diferentes, pero todas ellas tienen un origen común, las llamadas células madre embrionarias o células pluripotentes, capaces de transformarse en cualquier otro tipo. La reprogramación celular inducida consiste en activar cuatro genes concretos llamados cóctel de Yamanaka. El grupo de Manolo Serrano trataba de mejorar la técnica in vitro usando ratones modificados genéticamente con un gen artificial que activa el cóctel de Yamanaka en respuesta a la administración de un antibiótico llamado tetraciclina. Su intención era usar las células de estos ratones en una placa de cultivo e inducir la reprogramación usando el antibiótico in vitro. Un día a María Abad y sus colegas se les ocurrió administrar el antibiótico por vía oral a los ratones, diluido en el agua que bebían, y ver qué pasaba. No pensaban que sus células se fueran a reprogramar dentro del ratón vivo, pero probaron y les funcionó la idea. En ciertos tejidos las células se reprogramaron de forma descontrolada en el interior del cuerpo de los ratones y se formaron teratomas, una especie de tumor benigno o quiste de origen embrionario. Además, los investigadores del CNIO detectaron células madre pluripotentes en el torrente sanguíneo de los ratones.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

baseiro
Iniciandose
Mensajes: 20
Registrado: 22 Nov 2012 09:56

Re: Biotecnologicas

Mensajepor baseiro » 07 Oct 2013 12:31

Aquí tienes un interesante documental sobre los avances de la ciencia, y como la medicina regenerativa estudia el cultivo de órganos y partes del cuerpo.

"La Noche Temática. "El corazón autosuficiente"
http://www.rtve.es/television/20130924/ ... 7981.shtml

Impresionante lo que se se está consiguiendo ya.

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8868
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 10 Oct 2013 19:50

Google Ventures Managing Partner Bill Maris, who's been orchestrating a few high-profile investments in the biotech industry, is described as the corporate godfather of this endeavor. According to Primack, his explorations in the biopharma world led him to conclude that there are a lot of companies focused on diseases, but virtually no one trying to target the cellular degradation involved in aging, which is what causes many diseases and ultimately the death of us all.

With all the genetic sequencing tech available today, Maris believes that it's possible to discover the seemingly magic genetic formula that makes some 90-year-olds vigorous and healthy, while so many people either never get that far or only manage to do so in terrible health. And while Maris has been making the rounds raising cash, Fortune reports that Google corporate is content to invest "hundreds of millions" of dollars in the years-long effort at revolutionizing medicine.

One other note from Silicon Valley: Calico may wind up looking a lot more like a research institute initially than a traditional biopharma company.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8868
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 21 Nov 2013 17:14

Jim Simons sale de Biotecnologicas:

This may make him a biotech bear. Lastly, a noticeable trend in Simons’ latest filing is possible bearishness on two fairly major biotech names: Celgene (NASDAQ:CELG) and Biogen (NASDAQ:BIIB). Now, there are many reasons why a hedge fund manager would choose to sell shares of his or her stock, and Simons’ sales in Celgene and Biogen didn’t close out his positions entirely, but they’re curious nonetheless. He cut his stake in Celgene, an immune-inflammatory biotech giant, by 25%, and he cut his holdings of neurodegenerative/autoimmune biotech Biogen by 37%. Both stocks have returned at least 60% year-to-date, so profit-taking is a reasonable explanation for the moves.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8868
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 14 Mar 2014 21:27

RNA interference (“RNAi”) is a way of turning genes “on” and “off”: turning genes “on” to produce a protein that is otherwise lacking, or turning a gene “off” to halt production of a disease-causing protein. This technology is opening up a range of diseases that were previously not treatable to new-drug approaches. A lot of these are what we’d call “orphan diseases” with small patient populations—typically less than 200,000 people.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

McThai
Aprendiz de Especulador
Mensajes: 80
Registrado: 31 Oct 2012 00:45

Re: Biotecnologicas

Mensajepor McThai » 21 Mar 2014 19:51

Señales de un mercado demasiado sobrecalentado?
Adjuntos
biot.png

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8868
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 11 Jun 2014 04:21

Esta pinchando la burbuja de biotecnologicas? (http://inbestia.com/diarios-trading/ate ... tecnologia)
Adjuntos
biotech2.png
biotech1.png
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!


Volver a “Ideas de negocio”

Ingresar